The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
作者： M. C. Thomas , K. A. Jandeleit-Dahm , C. Tikellis
DOI: 10.1155/2012/456529
关键词:
摘要: Pharmaceutical agonists of peroxisome proliferator-activated receptors (PPARs) are widely used in the management type 2 diabetes, chiefly as lipid-lowering agents and oral hypoglycaemic agents. Although most focus has been placed on their cardiovascular effects, both positive negative, these also have significant renoprotective actions diabetic kidney. Over above action metabolic control effects blood pressure, PPAR appear to independent a number critical pathways that implicated development progression kidney disease, including oxidative stress, inflammation, hypertrophy, podocyte function. This review will examine direct indirect explore recent findings clinical trials patients with diabetes.
hindawi.com参考文章(115)
F. Ouali, F. Djouadi, C. Merlet-Bénichou, J. Bastin, Dietary lipids regulate β-oxidation enzyme gene expression in the developing rat kidney American Journal of Physiology-renal Physiology. ,vol. 275, ,(1998) , 10.1152/AJPRENAL.1998.275.5.F777
Ajay Chawla, Yaacov Barak, Laszlo Nagy, Debbie Liao, Peter Tontonoz, Ronald M. Evans, PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Medicine. ,vol. 7, pp. 48- 52 ,(2001) , 10.1038/83336
Giulia Chinetti, Sophie Lestavel, Virginie Bocher, Alan T. Remaley, Bernadette Neve, Inés Pineda Torra, Elisabeth Teissier, Anne Minnich, Michael Jaye, Nicolas Duverger, H. Bryan Brewer, Jean-Charles Fruchart, Véronique Clavey, Bart Staels, PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine. ,vol. 7, pp. 53- 58 ,(2001) , 10.1038/83348
Chun‐Xia Yao, Wen‐Yan Li, Shu‐Feng Zhang, Shan‐Feng Zhang, Hai‐Feng Zhang, Ming‐Xi Zang, None, Effects of Doxorubicin and Fenofibrate on the Activities of NADH Oxidase and Citrate Synthase in Mice Basic & Clinical Pharmacology & Toxicology. ,vol. 109, pp. 452- 456 ,(2011) , 10.1111/J.1742-7843.2011.00748.X
Chunhua Zhu, Songming Huang, Yanggang Yuan, Guixia Ding, Ronghua Chen, Bicheng Liu, Tianxin Yang, Aihua Zhang, Mitochondrial Dysfunction Mediates Aldosterone-Induced Podocyte Damage: A Therapeutic Target of PPARγ American Journal of Pathology. ,vol. 178, pp. 2020- 2031 ,(2011) , 10.1016/J.AJPATH.2011.01.029
Manjeri A Venkatachalam, H. G. Rennke, M. W. Seiler, R. S. Cotran, Pathogenesis of polycation-induced alterations ("fusion") of glomerular epithelium Laboratory Investigation. ,vol. 36, pp. 48- 61 ,(1977)
Mercedes Ricote, Andrew C. Li, Timothy M. Willson, Carolyn J. Kelly, Christopher K. Glass, The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation Nature. ,vol. 391, pp. 79- 82 ,(1998) , 10.1038/34178
Y.-T. Zhou, M. Shimabukuro, M.-Y. Wang, Y. Lee, M. Higa, J. L. Milburn, C. B. Newgard, R. H. Unger, Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 95, pp. 8898- 8903 ,(1998) , 10.1073/PNAS.95.15.8898
Youfei Guan, Yahua Zhang, Linda Davis, Matthew D. Breyer, Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans American Journal of Physiology-renal Physiology. ,vol. 273, ,(1997) , 10.1152/AJPRENAL.1997.273.6.F1013
Eric F. Johnson, Colin N. A. Palmer, Keith J. Griffin, Mei‐Hui Hsu, Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. The FASEB Journal. ,vol. 10, pp. 1241- 1248 ,(1996) , 10.1096/FASEBJ.10.11.8836037